MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.78
+0.66
+2.43%
Closed 18:19 03/31 EDT
OPEN
27.43
PREV CLOSE
27.12
HIGH
28.24
LOW
26.93
VOLUME
751.22K
TURNOVER
--
52 WEEK HIGH
55.12
52 WEEK LOW
15.19
MARKET CAP
3.51B
P/E (TTM)
-48.5410
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADPT stock price target is 44.75 with a high estimate of 46.00 and a low estimate of 43.00.

EPS

ADPT News

More
  • Hedge Funds Interest Was Stagnant In Adaptive Biotechnologies Corporation (ADPT) Before The Coronavirus
  • Insider Monkey · 4d ago
  • Microsoft, Adaptive partner to better diagnose COVID-19 in research with implications for future pandemics
  • American City Business Journals · 03/24 21:45
  • Microsoft, Adaptive Biotech Collaborate to Fight COVID-19
  • Zacks · 03/23 16:06
  • Chad Cohen shares his IPO playbook after leading two Seattle companies through theirs
  • American City Business Journals · 03/20 19:00

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About ADPT

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
More

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.